ZYNE Stock: Zynerba Pharmaceuticals Reaches $13.07 After 4.00% Up Move; 7 Bullish Analysts Covering Descartes Systems Group

0
82

The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is a huge mover today! About 358,768 shares traded. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has risen 161.36% since November 14, 2016 and is uptrending. It has outperformed by 144.66% the S&P500.The move comes after 9 months positive chart setup for the $173.27 million company. It was reported on Nov, 14 by Barchart.com. We have $13.59 PT which if reached, will make NASDAQ:ZYNE worth $6.93M more.

Among 8 analysts covering Descartes Systems Group (TSE:DSG), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Descartes Systems Group had 29 analyst reports since August 28, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Outperform” rating and $34 target in Monday, November 28 report. RBC Capital Markets maintained Descartes Systems Group Inc (TSE:DSG) rating on Friday, May 20. RBC Capital Markets has “Outperform” rating and $27.50 target. Scotia Capital maintained Descartes Systems Group Inc (TSE:DSG) on Thursday, December 1 with “Outperform” rating. The company was maintained on Friday, November 25 by Scotia Capital. The rating was maintained by RBC Capital Markets on Friday, March 31 with “Outperform”. As per Friday, June 17, the company rating was maintained by Scotia Capital. RBC Capital Markets maintained it with “Outperform” rating and $28 target in Monday, November 30 report. The rating was maintained by Scotia Capital on Friday, September 9 with “Outperform”. The rating was maintained by Scotia Capital with “Outperform” on Wednesday, August 31. The stock of Descartes Systems Group Inc (TSE:DSG) earned “Market Perform” rating by BMO Capital Markets on Thursday, June 1. See Descartes Systems Group Inc (TSE:DSG) latest ratings:

08/09/2017 Broker: Raymond James Rating: Outperform New Target: $38.00 Target Up
01/09/2017 Broker: RBC Capital Markets Rating: Outperform New Target: $40.00 Target Up
01/06/2017 Broker: BMO Capital Markets Rating: Market Perform New Target: $35.00 Maintain
01/06/2017 Broker: Canaccord Genuity Rating: Buy New Target: $38.00 Target Up
01/06/2017 Broker: Raymond James Rating: Outperform New Target: $37.00 Target Up
01/06/2017 Broker: Scotia Capital Rating: Outperform New Target: $38.00 Target Up
01/06/2017 Broker: TD Securities Rating: Buy New Target: $39.00 Target Up

Descartes Systems Group Inc is a Canada global well-known provider of federated network and global logistics technology solutions that help its clients make and receive shipments and manage related resources. The company has market cap of $2.91 billion. The Company’s network solutions, which primarily consist of services and software, connect people to their trading partners and enable business document exchange (bookings, bills of lading, status messages); regulatory compliance and customs filing; route and resource planning, execution and monitoring; access and leverage global trade and restricted party data; inventory and asset visibility; rate and transportation management, and warehouse operations. It has a 87.46 P/E ratio. The Company’s solutions include Logistics Technology Platform that fuses the Descartes Global Logistics Network (Descartes GLN); customs and regulatory compliance; routing, mobile and telematics; global logistics network services; transportation management, and broker and forwarder enterprise systems.

About 7,590 shares traded. Descartes Systems Group Inc (TSE:DSG) has 0.00% since November 14, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 6 analysts covering Zynerba Pharmaceuticals (NASDAQ:ZYNE), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Zynerba Pharmaceuticals has $42 highest and $22 lowest target. $32.17’s average target is 146.14% above currents $13.07 stock price. Zynerba Pharmaceuticals had 8 analyst reports since August 31, 2015 according to SRatingsIntel. On Thursday, December 22 the stock rating was initiated by Cantor Fitzgerald with “Overweight”. Oppenheimer maintained the shares of ZYNE in report on Thursday, November 12 with “Outperform” rating. The rating was initiated by Jefferies on Monday, August 31 with “Buy”. Piper Jaffray initiated Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) rating on Monday, August 31. Piper Jaffray has “Overweight” rating and $42 target. The stock has “Outperform” rating by Oppenheimer on Tuesday, September 8. H.C. Wainwright initiated Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) rating on Friday, October 7. H.C. Wainwright has “Buy” rating and $22 target. As per Monday, September 14, the company rating was initiated by Canaccord Genuity.

LEAVE A REPLY

Please enter your comment!
Please enter your name here